You are here

Managing Adverse Effects

Active Resources: 8

Archive Resources: 2

Articles: 5

  • Weight Gain and Metabolic Complications with ART: Data from AIDS 2020

    Susa Coffey's picture

    Over the past few years, numerous studies have examined weight gain in people with HIV who start or change antiretroviral therapy (ART). While it is clear that some people gain excessive amounts of weight after starting (and sometimes upon changing) ART, the roles of specific antiretroviral (ARV...

  • Safety of Dolutegravir at Conception: Updated Data

    Susa Coffey's picture

    In 2018, initial results from the Tsepamo study of birth outcomes in Botswanan women treated with ART during pregnancy raised questions about the safety of dolutegravir (DTG) when given at the time of conception or very early in pregnancy. Specifically, an early interim analysis found a higher...

  • Recap: 17th Ryan White HIV/AIDS Program Clinical Care Conference

    Laura Cheever's picture

    Highlights from Laura W. Cheever, MD, ScM, HRSA HIV/AIDS Bureau Associate Administrator and Conference Co-Chair

    The field of HIV/AIDS care and treatment continues to evolve rapidly. Groundbreaking developments in HIV research are regularly presented at international...

  • Switching from TDF/FTC to TAF/FTC

    Susa Coffey's picture

    Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg...

  • Cobicistat and Stribild Use in Patients with Renal Insufficiency

    Ian R. McNicholl's picture

    Co-Author: Susa Coffey, MD; Medical Editor, AETC National Resource Center

    An open-label study is evaluating the renal safety of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild, or the "quad" pill) and cobicistat. For those patients with mild-to-...